Imipenem & Cilastatin For Inj. 1gm /2gm

What is Imipenem & Cilastatin for Injection 1 g / 2 g?

Imipenem & Cilastatin for Injection is a combination antibacterial product containing imipenem, a carbapenem antibiotic, and cilastatin, which helps prevent imipenem breakdown by a kidney enzyme. It is used by healthcare professionals for selected serious bacterial infections caused by susceptible organisms. The exact formulation, component strengths and preparation requirements should be confirmed against the approved product information.

Uses / Indications

Imipenem and cilastatin may be used for selected bacterial infections caused by susceptible organisms. Approved indications depend on the product formulation, infection site, bacterial susceptibility and the patient’s clinical condition.

Benefits

• Combines a carbapenem antibiotic with an enzyme inhibitor that reduces renal breakdown of imipenem.

• Provides an option for selected infections requiring broad-spectrum antibacterial treatment.

• Supports treatment decisions guided by susceptibility results and clinical assessment.

Side Effects

Possible side effects vary according to the patient, dose and treatment circumstances.

Common side effects

• Nausea or vomiting

• Diarrhoea

• Injection-site reactions

• Skin rash

Less common or serious side effects

• Severe allergic reactions

• Seizures or other central nervous system effects

• Severe or persistent diarrhoea

• Changes in liver function or blood cell counts

Seek urgent medical attention if severe allergic symptoms, seizures or other serious adverse effects occur.

How Does It Work?

Imipenem inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins, leading to bacterial cell death. Cilastatin inhibits renal dehydropeptidase-I, an enzyme that breaks down imipenem in the kidneys. This helps maintain imipenem availability. The combination’s effectiveness depends on organism susceptibility and appropriate clinical use.

Dosage Guidelines

The dose and treatment duration depend on the infection, its severity, bacterial susceptibility, patient age, kidney function and the approved formulation. Renal function is particularly important when determining an appropriate regimen.

The exact dose, administration route, frequency and treatment duration should follow the approved product information and the recommendation of a qualified healthcare professional.

Preparation and administration must follow the approved instructions for the specific product. Confirm the individual component strengths, supplied WFI configuration and whether the listed strengths represent the total formulation before use.

When Not to Use

• In patients with a known serious hypersensitivity to imipenem, cilastatin or relevant product components.

• In patients with a history of severe reactions to carbapenems or other beta-lactam antibiotics, unless a qualified healthcare professional has assessed the risks and suitability of treatment.

Drug / Product Interactions

Important interaction considerations include:

• Valproic acid or divalproex: Carbapenems can substantially reduce valproate concentrations and may increase seizure risk.

• Ganciclovir: Concurrent use may increase the risk of seizures in some patients.

• Other beta-lactam antibiotics: Concurrent treatment should be reviewed for clinical suitability.

• Medicines affecting kidney function: Additional monitoring may be necessary depending on the patient’s condition and medication regimen.

A healthcare professional should review all medicines before treatment and consult the approved product information for specific interactions.

Safety Advice

• Use only under the supervision of a qualified healthcare professional.

• Review the patient’s allergy history before administration.

• Assess kidney function and seizure risk where appropriate.

• Use antibiotics only for appropriate bacterial infections.

• Monitor for allergic reactions, neurological symptoms and other clinically significant adverse effects.

General Instructions

• Verify the product name, strength, component quantities and vial presentation before use.

• Follow the approved instructions for preparation and administration.

• Do not use damaged packaging or a vial that does not meet the required specifications.

• Confirm storage conditions and instructions for use after preparation from the approved product label.

• Do not assume a specific WFI volume, diluent compatibility or post-preparation shelf life without verified product information.

Special Dietary / Lifestyle Tips

No specific diet is universally required solely because of imipenem and cilastatin treatment. Patients should follow their healthcare professional’s advice, maintain hydration when appropriate and report new neurological symptoms or other unexpected effects promptly.

Comparison with Other Treatments

Imipenem belongs to the carbapenem class of beta-lactam antibiotics, while cilastatin helps reduce imipenem breakdown in the kidneys. Other carbapenems and antibiotic classes have different activity profiles, indications and safety considerations. Treatment selection should depend on bacterial susceptibility, infection severity, local resistance patterns and patient-specific factors. Carbapenems should be used judiciously to help preserve their effectiveness.

Precautions & Warnings

• Allergy risk: Confirm any history of serious reactions to carbapenems, penicillins or other beta-lactam antibiotics.

• Kidney function: Impaired renal function may affect dosing and safety.

• Seizure risk: Neurological adverse effects may occur, particularly in patients with relevant risk factors or inappropriate dosing.

• Drug interactions: The interaction with valproate medicines is especially important.

• Antibiotic resistance: Use should be guided by clinical need and susceptibility information.

• Product verification: Confirm the individual component strengths and approved vial preparation requirements before use.

Can I Use It With Other Medicines?

Generally Compatible With

Other medicines may be used when clinically indicated, subject to review by the treating healthcare professional and the approved product information.

Use With Caution

• Valproic acid or divalproex

• Ganciclovir

• Other antibiotics

• Medicines requiring additional kidney function or neurological monitoring

Avoid

Carbapenems are generally not recommended with valproic acid or divalproex because they can markedly reduce valproate concentrations. Avoid use in patients with a known serious hypersensitivity to the product or relevant antibiotics. Do not mix the product with other medicines unless compatibility is established by the approved product information.

Storage

Store according to the conditions stated on the approved product label. Follow product-specific instructions for preparation, handling and use after reconstitution. Do not assume a storage temperature or post-preparation shelf life without verified product information.

Frequently Asked Questions

1. What is Imipenem & Cilastatin for Injection used for?

It is used for selected bacterial infections caused by susceptible organisms, according to the approved product information and clinical assessment.

2. What are the active ingredients?

The product contains imipenem and cilastatin.

3. What strengths are listed?

The supplied description lists 1 g and 2 g. Confirm whether these represent combined strengths or individual component quantities.

4. What is the role of cilastatin?

Cilastatin inhibits an enzyme in the kidneys that breaks down imipenem, helping maintain imipenem availability.

5. Does the product come with WFI?

The supplied description specifies a vial with WFI. The exact presentation and preparation requirements should be confirmed against the approved product specification.

6. Can this combination cause seizures?

Seizures and other neurological effects are possible, particularly in patients with risk factors or impaired kidney function. Clinical assessment and appropriate dosing are important.

7. Can it be used with valproate medicines?

This combination is generally not recommended because carbapenems can substantially reduce valproate concentrations and increase seizure risk. A healthcare professional should assess alternatives.

8. Can Kelar Pharmachem India support sourcing enquiries?

Kelar Pharmachem India supports pharmaceutical sourcing and export enquiries. Product specifications, supporting documentation and destination-market requirements are subject to confirmation.